Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

RetinDR

Financiado

Cerrado

RetinDR The first topical ophthalmic formulation eye drops that effectively p...

RetinDR The first topical ophthalmic formulation eye drops that effectively prevents and or treats the retinal neurodegeneration induced by diabetes diabetic retinopathy and or aging Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer this disease. The early stages of DR usually have no symptoms, however when t... ver más

31/01/2020

RETINSET

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

RETINSET El estudio, investigacion, desarrollo, fabricacion, distribucion, comercializacion, suministros y venta de productos y formulaciones farmace...

TRL 4-5 | 124K€

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-01-31

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

RETINSET

50.00K€ | Lider

PREMIUM INGREDIENTS

686.74K€ | Participante

Proyectos interesantes

RTC-2015-4400-1

Medical Technol...

Biomedical Devi...

199K€ Cerrado

DESARROLLO CLÍNICO DE RETSIT@, UN FÁRMACO NEU...

Medical Technol...

Pharmaceutical...

250K€ Cerrado

PTQ-09-01-00826

Medical Technol...

Medical Devices

49K€ Cerrado

SAF2014-62114-EXP

Medical Technol...

Ophthalmology

73K€ Cerrado

EUROCONDOR

Medical Technol...

Data Science

8M€ Cerrado

SAF2016-77784-R

Medical Technol...

Ophthalmology

266K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 6 meses Fecha Inicio: 2019-07-21
Fecha Fin: 2020-01-31

Líder del proyecto

RETINSET El estudio, investigacion, desarrollo, fabricacion, distribucion, comercializacion, suministros y venta de productos y formulaciones farmace...

TRL 4-5 | 124K€

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults. About 93 million people worldwide and 3%-4.1% of Europeans suffer this disease. The early stages of DR usually have no symptoms, however when the disease progresses it affects vision: blurred vision, seeing double, difficulty reading, spots or floaters in the field of vision, and loss of peripheral vision. Current treatments are quite aggressive, are only indicated in advanced stages of the disease, have significant side effects and their effectiveness is limited. RetinDR is a topical ophthalmic formulation (eye drops) that effectively prevents and/or treats the retinal neurodegeneration induced by diabetes (diabetic retinopathy) and/or aging. The pharmaceutical development of RetinDR is based on the repurposing of the drug substance bosentan (endothelin receptor antagonist, currently indicated for the pulmonary arterial hypertension treatment) for the prevention and treatment of DR. The global DR market accounted for $5.81B in 2016 and is forecast to grow at 6.3%. CAGR till 2025. We estimate a market share of 0.115% 5 years after commercialisation, equalling revenues of 52M€. Our main business model will focus on sales and distribution of RetinDR in Europe through a distribution agreement with the parent company Medical Mix S.L. and co-development or licensing agreements with strategic industrial partners in markets outside of Europe where we will receive royalties. With this model and the successful completion of the SME Phase 1 and 2 we estimate an EBITDA of over 55M€ in 5 years after commercialization an IRR of 98% and NPV of over 21M€ considering a WACC of 15%, creating 22 new jobs by 2025. The Feasibility Study for this project will take 6 months and focus on an in-depth market study, technical testing and the development of final business plan to take us to market.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores